This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Coen, J. J. Articles by Shipley, W. U. Search for Related Content PubMed PubMed Citation Articles by Coen, J. J. Articles by Shipley, W. U. Social Bookmarking                            What's this?

Radical Radiation for Localized Prostate Cancer: Local Persistence of Disease Results in a Late Wave of Metastases

From the Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA.

Address reprint requests to John Coen, MD, Department of Radiation Oncology, Massachusetts General Hospital, 100 Blossom St, Cox 3, Boston, MA 02114; email: jcoen{at}partners.org

PURPOSE: To assess whether failure to maintain local control (LC) of prostate cancer after radiation therapy results in a higher incidence of distant metastasis (DM).

PATIENTS AND METHODS: From 1972 to 1999, 1,469 patients with clinically localized prostate cancer were treated with radical radiation therapy. Disease outcome was retrospectively reviewed for all patients with more than 2 years of follow-up.

RESULTS: The actuarial 10-year LC rate was 79%. Gleason score 7, prostate-specific antigen (PSA) more than 15, and T3 to T4 tumors predicted a higher incidence of local failure (LF) (palpable recurrence or positive rebiopsy). The 10-year distant metastasis-free survival (DMFS) was 74%. Gleason score 7, PSA more than 15, and T3 to T4 tumors predicted a higher incidence of distant failure. LF was the strongest predictor for DM in a multivariate model. The 10-year DMFS for LC and LF patients was 77% and 61%, respectively. Median time to distant failure was prolonged in patients with LF compared with patients with locally controlled disease (54 v 34 months). Hazard rate analysis of the time to DM revealed that patients who maintain LC have a lower rate of DM, which remains constant over time. Patients who ultimately develop LF have a higher initial rate of DM, which increases with time.

CONCLUSION: Patients with locally persistent prostate cancer are at greater risk of DM. The higher initial hazard of DM is consistent either with an increased likelihood of subclinical micrometastases before treatment or with posttreatment tumor embolization. The prolonged time to appearance of DM in locally failing patients and the increasing hazard of DM over time is most consistent with a late wave of metastases from a locally persistent tumor.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				T. Wiegel, D. Bottke, U. Steiner, A. Siegmann, R. Golz, S. Storkel, N. Willich, A. Semjonow, R. Souchon, M. Stockle, et al. Phase III Postoperative Adjuvant Radiotherapy After Radical Prostatectomy Compared With Radical Prostatectomy Alone in pT3 Prostate Cancer With Postoperative Undetectable Prostate-Specific Antigen: ARO 96-02/AUO AP 09/95 J. Clin. Oncol., June 20, 2009; 27(18): 2924 - 2930. [Abstract] [Full Text] [PDF]

				C. Kadoch, A. V. D'Amico, and R. H. Matthews When Prostate Brachytherapy Fails: A Case Report and Discussion Oncologist, November 1, 2005; 10(10): 799 - 805. [Abstract] [Full Text] [PDF]

				T. Sella, L. H. Schwartz, P. W. Swindle, C. N. Onyebuchi, P. T. Scardino, H. I. Scher, and H. Hricak Suspected Local Recurrence after Radical Prostatectomy: Endorectal Coil MR Imaging Radiology, May 1, 2004; 231(2): 379 - 385. [Abstract] [Full Text] [PDF]

				M. W. Kattan, M. J. Zelefsky, P. A. Kupelian, D. Cho, P. T. Scardino, Z. Fuks, and S. A. Leibel Pretreatment Nomogram That Predicts 5-Year Probability of Metastasis Following Three-Dimensional Conformal Radiation Therapy for Localized Prostate Cancer J. Clin. Oncol., December 15, 2003; 21(24): 4568 - 4571. [Abstract] [Full Text] [PDF]

				R. Enmon, W.-H. Yang, A. M. Ballangrud, D. B. Solit, G. Heller, N. Rosen, H. I. Scher, and G. Sgouros Combination Treatment with 17-N-Allylamino-17-Demethoxy Geldanamycin and Acute Irradiation Produces Supra-Additive Growth Suppression in Human Prostate Carcinoma Spheroids Cancer Res., December 1, 2003; 63(23): 8393 - 8399. [Abstract] [Full Text] [PDF]

				C. J. Logothetis Challenge of Locally Persistent Prostate Cancer: An Unresolved Clinical Dilemma J. Clin. Oncol., August 1, 2002; 20(15): 3187 - 3187. [Full Text] [PDF]